Stock Ticker

  • Loading stock data...

Pfizer Inc. (NYSE:PFE) To Merge Its Off-Patent Business With Mylan (NASDAQ:MYL)

There are reports indicating that Pfizer Inc. (NYSE:PFE) wants to merge its off-patent drug operations in a stock deal with generic drug maker Mylan (NASDAQ:MYL) whose market value is estimated at $9.5 billion. Pfizer to get $12 billion from sale of debt The pharmaceutical company is will spin off its new unit so that it […]

Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) Announces Gregory Naeve As Chief Business Officer

Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) reported that the company has appointed Gregory Naeve, Ph.D., as Chief Business Officer. Dr. Naeve will lead portfolio and product strategy and business development for the firm. The details Rick Fair, the CEO and President of Bellicum, reported that they are thrilled to welcome a leader of Dr. Naeve’s caliber and […]

The Incyte Rheumatoid Arthritis Pill Setback Poses Disagreements With FDA, As Pfizer Inc (NYSE:PFE) And Others Stand To Gain

The recent turn of events in some of the top stocks have raised eyebrows worldwide, but what Eli Lilly and Co (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) have become the highest talk cutting through the air! The two chose Friday, which as a matter of fact happens to be a market holiday to actually disclose the […]

Pfizer Inc. (NYSE:PFE) Wins A $40 Million Bid By BIND Therapeutics Inc (NASDAQ:BIND)

Pfizer Inc. (NYSE:PFE) was the winner of a $40 million bid by BIND Therapeutics Inc (NASDAQ:BIND). PFE succeeded at a Section 363 auction initiated by the Cambridge, Massachusetts-based biotechnology company which is selling off its assets. Among other two unidentified companies that had joined the auction Pfizer’s bid was selected as the highest and best. […]

Pfizer Inc. (NYSE:PFE) Is All Set To Present New Vaccine Candidate at IDWeek 2014

Boston, MA 10/13/2014 (wallstreetpr) – According to reports, Pfizer Inc. (NYSE:PFE) has announced that it would present the phase-1 and phase-2 study data of the recent study that it conducted about a new vaccine candidate. The presentation will be made during IDWeek 2014. Insights of the study: Pfizer Inc. (NYSE:PFE) conducted a study for evaluation […]

Pfizer Inc. (NYSE:PFE) Offers Financial Grants Worth $2 Million For Vaccination Coverage In Africa

Boston, MA 09/22/2014 (wallstreetpr) – Africa remains prone to diseases and with the absence of immunization; some of the ailments may eventually become fatal. As a part of its corporate responsibility, the Pfizer Inc. (NYSE:PFE) Foundation announced that it would offer a financial grant worth $2 million for a few pilot programmes in Africa. The […]

VIVUS, Inc. (NASDAQ:VVUS) – Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) Stendra Gets FDA Go-Ahead For 15 Minutes Prior Use

Boston, MA 09/19/2014 (wallstreetpr) – Stendra, the erectile dysfunction drug developed collaboratively by VIVUS, Inc. (NASDAQ:VVUS) and Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) has been given the nod by the U.S. Food and Drug Administration to be used 15 minutes earlier. It is crucial to point out here that this drug was already approved by the FDA, […]

Pfizer Inc. (NYSE:PFE) Can Raise Its Bid For AstraZeneca plc (ADR) (NYSE:AZN)

Boston, MA 08/25/2014 (wallstreetpr) – It seems Pfizer Inc. (NYSE:PFE) is adamant for an overseas takeover to get the tax inversion benefits and expand its product portfolio. It can place a renew bid for AstraZeneca plc (ADR) (NYSE:AZN), on November 26, 2014. But if AstraZeneca wants, it can invite Pfizer for further discussion after August […]

Pfizer Inc. (NYSE:PFE) And Bristol-Myers Squibb Co (NYSE:BMY) Announced FDA Clearance For Eliquis For Blood Clots Treatment

Boston, MA 08/22/2214 (wallstreetpr) – Pfizer Inc. (NYSE:PFE) and Bristol-Myers Squibb Co (NYSE:BMY) announced recently that the USFDA has given an extension of approving Eliquis, the blood thinner, which shall be used for the treatment of fatal blood clots. The treatment of two kinds of blood clots can be done by way of this blood […]

Pfizer Inc. (NYSE:PFE) Decides To Submit The Marketing Application For Palbociclib To the FDA

Boston, MA 08/20/2014 (wallstreetpr) – According to reports, Pfizer Inc. (NYSE:PFE) has decided to submit the marketing application for Palbociclib; oncology candidate of the company to the FDA. The company wants to get approval in regard with approval of Femara (letrozole) of Novartis. It is used for the treatment of postmenopausal women with estrogen receptor-positive […]

Pfizer Inc. (NYSE:PFE) Submits New Drug Application For Palbociclib

Boston, MA 08/19/2014 (wallstreetpr) – Research-based global pharmaceutical firm Pfizer Inc. (NYSE:PFE) had submitted a New Drug Application or NDA to the Food and Drug Administration or the FDA for its palbociclib. The company seeks the FDA permission of palbociclib to be combined with letrozone for treating postmenopausal women of estrogen receptor positive or ER+, […]

Pfizer Inc. (NYSE:PFE)’s Emilio Emini Views FDA Acceptance As Significant Regulatory Milestones

Boston, MA 08/15/2014 (wallstreetpr) – Research-based global biopharmaceutical company, Pfizer Inc. (NYSE:PFE)’s vice president Emilio Emini termed the U.S. Food and Drug Administration or FDA acceptance of its Biologics License Application or BLA and the Priority Review designation as significant regulatory milestones. FDA Accepts The Pfizer Inc. (NYSE:PFE) disclosed that the drug regulator had accepted […]

Abbvie Inc (NYSE:ABBV), Pfizer Inc. (NYSE:PFE) Struck In Tax Inversions Amid Political Pressure; Walgreen Company (NYSE:WAG) To Remain Headquartered In Illinois Despite Boots’ Acquisition

Boston, MA 08/07/2014 (wallstreetpr) – Walgreen Company (NYSE:WAG) on August 6, 2014 announced about its plan for shelling out approximately $15.3 billion for acquisition of Alliance Boots’ portion that it does not own yet. However, Walgreen said that it will not be using this deal for corporate inversion. The shares of company sunk to the […]

Pfizer Inc. (NYSE:PFE) To Shed Out $35 Million From Its Pocket To Settle Wyeth Wyeth Pharmaceuticals’s Unlawful Drug Marketing Case

Boston, MA 08/07/2014 (wallstreetpr) – In the case involving illegal marketing of a drug associated with organ transplant, Pfizer Inc. (NYSE:PFE) will shed out $35 million from its pocket. The amount shall be paid in order to settle allegations from 42 different states that the company’s subsidiary, Wyeth Pharmaceuticals marketed this drug for unlawful uses. […]

Mylan Inc. (NASDAQ:MYL) Manages license Agreement With Pfizer Inc. (NYSE:PFE) For Generic Version Of Celebrex

Boston, MA 06/04/2014 (wallstreetpr) – Mylan Inc. (NASDAQ:MYL) made an official announcement about its license agreement to sell the generic version of the painkiller capsules Celecoxib, also referred popularly as Celebrex, with Pfizer Inc. (NYSE:PFE). Abbreviated New Drug Application (ANDA) In answer to the aforementioned application made by Mylan Inc. (NASDAQ:MYL) to the US FDA, […]

Sign Up To Get Our Latest Stocks Alerts